Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate
Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...
BioSpace15d
GLP-1 Side Effects Only One Factor Driving Patient Discontinuation Rates
While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that myriad variables are causing patients to stop treatment.
BioSpace8d
GLP-1 Players Seek to Differentiate in Increasingly Crowded Weight Loss Space
As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...
BenefitsPRO13d
Holistic approach can help employers offer GLP-1 coverage while holding the line on cost
Coverage of GLP-1s is not necessarily in-your-face obvious. It leads to the conversation of whether we want to pursue weight ...
American Chemical Society2d
Improving GLP-1 drug delivery by ‘painting’ it on antibodies
Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss., ...
Healio11d
GLP-1 drugs may extend life, graft survival for kidney transplant recipients with diabetes
Kidney transplant recipients with type 2 diabetes prescribed GLP-1 receptor agonists had 31% lower mortality vs. nonusers. GLP-1 receptor agonist use was associated with 49% lower incidence of ...
The Victoria Advocate11d
Biolexis Therapeutics Unlocks a New Frontier in GLP-1 Receptor Activation
structure of BLX-7006, its first-in-class oral small-molecule GLP-1 receptor agonist. This breakthrough confirms a completely novel allosteric activation mechanism for the GLP-1 receptor ...